- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03347383
Clinical Trial Investigating the Combination Therapy With Luminor DCB and iVolution Stent in TASC C and D Femoropopliteal Lesions (TINTIN)
Physician Initiated, Prospective, Non-randomized Belgian Multi-center Trial, Investigating the Safety and Efficacy of the Treatment With the LumINor DCB and The IvolutioN Stent of iVascular in TASC C and D Femoropopliteal Atherosclerotic Disease
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The objective of this clinical investigation is to evaluate, in a controlled setting, the long-term safety and efficacy of the combination therapy with the Luminor DCB and the iVolution stent post CE-certification and according to the indications of the Instructions for use (IFU) with focus on the treatment of TASC C and D femoropopliteal atherosclerotic lesions.
Patients will be selected based on the investigator's assessment, evaluation of the underlying disease and the eligibility criteria. The patient's medical condition should be stable, with no underlying medical condition which would prevent them from performing the required testing or from completing the study. Patients should also be geographically stable, willing and able to cooperate in this clinical study and remain available for long-term follow-up. A patient is considered enrolled in the study after obtaining the patients informed consent, if there is full compliance with the study eligibility criteria and after successful guidewire passage through the study target lesion.
Prior to the index procedure the following tests and clinical data will be collected: informed consent for data collection, demographics, medical history, medication record, physical examination, clinical category of chronic limb ischemia (Rutherford category) and resting ankle-brachial index (ABI).
During the procedure, the vascular access can be achieved to the investigator's standard clinical practice. After successful lesion passage, diagnostic angiography of the lesion area and distal run-off is performed and angiographic measurements (vessel diameter, percentage stenosis and lesion length) are collected. All inflow-limiting lesion will be treated according to the investigators standard clinical practice before treatment of the target lesion. Pre-dilatation of the target lesion is mandatory with the Oceanus balloon. After pre-dilatation, a least one Luminor DCB will be inflated and at least 1 iVolution stent will be deployed at the target lesion. At the physician's discretion, post-dilatation can be performed. No other adjunctive therapies (atherectomy, laser) are allowed. The complete femoropopliteal vasculature should be treated in one single session, staged interventions are not allowed. All outflow-limiting lesions must be treated according to the hospital treatment standard.
The regular follow-ups are necessary to monitor the condition of the patient and the procedure. Patients will be invited for a follow-up visit at 1, 6, 12, 24, 36, 48 and 60 months after the index procedure. The 24, 36, 48 and 60 month follow-up can be conducted via a phone call. The following data will be collected during these follow-up visit: medication record, physical examination, rutherford categorization, ABI and color flow doppler ultrasound.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Aalst, Belgium, 9300
- O.L.V. Hospital
-
Antwerpen, Belgium, 2060
- Z.N.A.
-
Bonheiden, Belgium, 2820
- Imelda Hospital
-
Bornem, Belgium
- Sint-Jozefkliniek
-
Dendermonde, Belgium, 9200
- A.Z. Sint-Blasius
-
Lier, Belgium
- H. Hartziekenhuis
-
Oostende, Belgium
- AZ Damiaan
-
Tienen, Belgium, 3300
- R.Z. Heilig Hart
-
Vilvoorde, Belgium
- AZ Jan Portaels
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
General inclusion criteria:
- Patient presenting a score from 2 to 5 following Rutherford classification
- Patient is willing to comply with specified follow-up evaluations at the specified times
- Patient is >18 years old
- Patient understands the nature of the procedure and provides written informed consent, prior to enrolment in the study
- Patient has a projected life expectancy of at least 12 months
- Prior to enrolment, the guidewire has crossed target lesion
- Patient is eligible for treatment with the Luminor Paclitaxel-Eluting Peripheral Balloon Dilatation Catheter and the iVolution stent
- Male, infertile female or female of child bearing potential practicing an acceptable method of birth control with a negative pregnancy test within 7 days prior to study procedure
Angiographic inclusion criteria
- De novo and post-percutaneous transluminal angioplasty (PTA) restenotic lesions located in the femoropopliteal arteries suitable for endovascular therapy
- The target lesion is located within the native femoropopliteal artery
- The length of the target lesion is ≥ 150mm and considered as TASC C or D lesion according to the TASC II classification.
- The target lesion has angiographic evidence of stenosis > 50% or occlusion which can be passed with standard guidewire manipulation
- Target vessel diameter visually estimated is >4mm and <6.5 mm
- There is angiographic evidence of at least one-vessel-runoff to the foot, irrespective of whether or not outflow was re-established by means of previous endovascular intervention
Exclusion Criteria:
- Patient refusing treatment
- Presence of a stent in the target lesion that was placed during a previous procedure
- Untreated flow-limiting inflow lesions
- Any previous surgery in the target vessel (including prior ipsilateral crural bypass)
- Patients for whom antiplatelet therapy, anticoagulants or thrombolytic drugs are contraindicated
- Patients who exhibit persistent acute intraluminal thrombus of the proposed lesion site
- Perforation at the angioplasty site evidenced by extravasation of contrast medium
- Patients with known hypersensitivity to heparin, including those patients who have had a previous incidence of heparin-induced thrombocytopenia (HIT) type II
- Patients with uncorrected bleeding disorders
- Aneurysm located at the level of the superficial femoral artery/popliteal artery
- Non-atherosclerotic disease resulting in occlusion (e.g. embolism, Buerger's disease, vasculitis)
- Severe medical comorbidities (severe chronic obstructive pulmonary disease, metastatic malignancy, dementia, etc.) or other medical condition that would preclude compliance with the study protocol or 1-year life expectancy
- Major distal amputation (above the transmetatarsal) in the study limb or non-study limb
- Septicemia or bacteremia
- Use of thrombectomy, atherectomy or laser devices during procedure
- Any patient considered to be hemodynamically unstable at onset of procedure
- Known allergy to contrast media that cannot be adequately pre-medicated prior to the study procedure
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Combination therapy DCB + stent
Patients treated with the Luminor DCB and the iVolution stent
|
Patients will be treated with the Luminor DCB and iVolution stent
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Freedom from clinically-driven TLR at 12 months
Time Frame: 12 months
|
TLR defined as a repeated intervention to maintain or re-establish patency within the region of the treated arterial vessel plus 5mm proximal and distal to the treated lesion edge at the respective time points.
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Primary patency rate
Time Frame: 6 and 12 months post-procedure
|
Absence of a hemodynamically significant stenosis on duplex ultrasound (systolic velocity ratio no greater than 2.5) at the target lesion and without TLR within the time of the procedure and the given follow-up.
|
6 and 12 months post-procedure
|
Technical success
Time Frame: Index procedure
|
Ability to cross and dilate the lesion and achieve residual angiographic stenosis no greater than 30%
|
Index procedure
|
Freedom from clinically-driven TLR
Time Frame: 6, 24, 36, 48 and 60 months post-procedure
|
TLR defined as a repeated intervention to maintain or re-establish patency within the region of the treated arterial vessel plus 5mm proximal and distal to the treated lesion edge at the respective time points.
|
6, 24, 36, 48 and 60 months post-procedure
|
Clinical success
Time Frame: 1, 6, 12, 24, 36, 48 and 60 months post-procedure
|
Improvement of Rutherford classification compared to the pre-procedure Rutherford classification
|
1, 6, 12, 24, 36, 48 and 60 months post-procedure
|
Serious Adverse Events (SAEs)
Time Frame: 1, 6, 12, 24, 36, 48 and 60 months post-procedure
|
Defined according to the Internal Organization of Standardization (ISO) guidelines: ISO 14155:2011
|
1, 6, 12, 24, 36, 48 and 60 months post-procedure
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Koen Deloose, M.D., ID3 Medical
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ID3-20170628
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Peripheral Arterial Disease
-
University of NebraskaNot yet recruitingPeripheral Arterial Disease | Peripheral Vascular Diseases | Peripheral Arterial Occlusive Disease | Peripheral Artery DiseaseUnited States
-
CID S.p.A.Meditrial Europe Ltd.Not yet recruitingPeripheral Arterial Occlusive Disease | Peripheral Artery DiseaseItaly
-
Marissa JarosinskiRecruitingPeripheral Arterial Occlusive Disease | Peripheral Vascular Disease | Peripheral Artery Disease | Clopidogrel, Poor Metabolism of | Artery DiseaseUnited States
-
Stanford UniversityTerminatedPAD - Peripheral Arterial Disease | PVD- Peripheral Vascular DiseaseUnited States
-
Vascuros Medical Pte LtdNovella ClinicalUnknownPeripheral Arterial Occlusive Disease | Peripheral Vascular Disease | Peripheral Artery DiseaseSingapore, Belgium, Germany
-
Western Vascular Institute, IrelandRecruitingPeripheral Arterial Occlusive DiseaseIreland
-
Jena University HospitalAngioDroid s.r.l., Bologna (Italy)CompletedPeripheral Arterial Occlusive DiseaseGermany
-
Seoul National University HospitalAstellas Pharma Korea, Inc.CompletedPeripheral Arterial Occlusive DiseaseKorea, Republic of
-
Heidelberg UniversityTerminatedPeripheral Arterial Occlusive DiseaseGermany
-
Johann Wolfgang Goethe University HospitalSuspendedPeripheral Arterial Occlusive DiseaseGermany
Clinical Trials on Combination therapy DCB + stent
-
Yonsei UniversityRecruitingFemoropopliteal Artery DiseaseKorea, Republic of
-
Xuanwu Hospital, BeijingRecruiting
-
Chinese PLA General HospitalUnknown
-
Seoul National University HospitalUnknownKor PCI - CAD Patients Treated With PCI: Analysis of the Korean Nationwide Health Insurance DatabaseCoronary Artery Disease | Drug-coated Balloon | Drug-eluting Stents
-
Shanghai MicroPort Medical (Group) Co., Ltd.Recruiting
-
Xuanwu Hospital, BeijingUnknownDiabetes | Popliteal Artery Occlusion | Popliteal StenosisChina
-
Deutsches Herzzentrum MuenchenAbbott; EvidentIQ Germany GmbH; Institute of AI and Informatics in Medicine Technical...RecruitingCoronary Artery Disease | Restenoses, CoronaryGermany
-
Rabih A. ChaerCompleted
-
North Karelia Central HospitalTurku University Hospital; Helsinki University Central Hospital; Oulu University... and other collaboratorsRecruitingCoronary Artery DiseaseFinland, France, Germany, United Kingdom
-
Clinical Hospital Center RijekaNot yet recruitingCoronary Artery Disease | Ischemic Heart Disease | Stable Angina | Unstable Angina | NSTEMI - Non-ST Segment Elevation MI